BioPharmaTrend
Latest News
All Topics
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers
  • Interviews
  • Business Intelligence
  • Case Studies
Intelligence
  • Business Intelligence
  • Case Studies
  • Lab
  • Membership
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Newsletter
Login/Join
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Industry Movers

  Latest News

Regeneron Acquires 23andMe Assets for $256M to Expand Consumer Genomics and Data-Driven Drug Discovery

by BiopharmaTrend   •   May 19, 2025  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Industry Movers   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Regeneron has announced an agreement to acquire substantially all assets of 23andMe for $256 million, following a bankruptcy auction process. The transaction, expected to close in Q3 2025 pending court and regulatory approvals, would include 23andMe’s Personal Genome Service, Total Health platform, and research services—along with its biobank and other associated assets. Notably, the deal does not include Lemonaid Health.

#advertisement
AI in Drug Discovery Report 2025

If approved, 23andMe would continue operations as a wholly owned subsidiary of Regeneron Pharmaceuticals, maintaining its consumer-facing genetic testing services. According to Regeneron, the acquisition is intended to both preserve 23andMe’s direct-to-consumer business and integrate its genomic assets into Regeneron’s broader genetics-guided drug development strategy.

See also: 23andMe Files for Bankruptcy

This move comes at a time when Regeneron is emphasizing scale in human genetics. Through its Genetics Center, the company has reportedly sequenced more than 2.7 million exomes, combining deidentified genomic data with EHRs for target discovery and validation. The 23andMe acquisition would bring in one of the most widely recognized consumer datasets in genomics built over more than a decade and create potential for new research pipelines, pending ethical, legal, and consent considerations.

Regeneron has pledged to uphold 23andMe’s existing privacy policies and work with a court-appointed Customer Privacy Ombudsman to ensure compliance and transparency. In statements, company executives framed the acquisition as an opportunity to responsibly unlock further value from large-scale genetic data while maintaining high standards for security and ethical oversight.

Topic: Industry Movers

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Newsletter
  • Business Intelligence
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Advertise
  • Lab Access
  • Lab Membership
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.